The feminization of HPV: How science, politics, economics and gender norms shaped U.S. HPV vaccine implementation
Open accessThe DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
Human papillomavirus (HPV) can cause a number of anogenital cancers (i.e., cervical, penile, anal, vaginal, vulvar) and genital warts. A decade ago, the HPV vaccine was approved, and has been shown to be a public health achievement that can reduce the morbidity and mortality for HPV-associated diseases. Yet, the mistaken over-identification of HPV as a female-specific disease has resulted in the feminization of HPV and HPV vaccines. In this critical review, we trace the evolution of the intersection of science, politics, economics and gender norms during the original HPV vaccine approval, marketing era, and implementation. Given the focus on cervical cancer screening, women were identified as bearing the burden of HPV infection and its related illnesses, and the group responsible for prevention. We also describe the consequences of the feminization of HPV, which has resulted primarily in reduced protection from HPV-related illnesses for males. We propose a multilevel approach to normalizing HPV vaccines as an important aspect of overall health for both genders. This process must engage multiple stakeholders, including providers, parents, patients, professional organizations, public health agencies, policymakers, researchers, and community-based organizations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Estimating the world cancer burden: Globocan 2000
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2001) · International Journal of Cancer · doi:10.1002/ijc.1440 · Cited by 3,721
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
Chaturvedi, A. K., Engels, E. A., Pfeiffer, R. M., Hernandez, B. Y., Xiao, W., Kim, E., Jiang, B., Goodman, M. T., Sibug-Saber, M., Cozen, W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.4596 · Cited by 3,638 · cited 1×
“, and it is projected that by 2020, HPV-related oropharyngeal cancers will exceed HPV-related cervical cancers [80].”
BackgroundMarkowitz, L. E., Dunne, E. F., Saraiya, M., Lawson, H. W., Chesson, H., & Unger, E. R. (2007) · PsycEXTRA Dataset · doi:10.1037/e601292007-001 · Cited by 1,882
Paavonen, J., Naud, P., Salmerón, J., Wheeler, C., Chow, S.-N., Apter, D., Kitchener, H., Castellsague, X., Teixeira, J., Skinner, Sr., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61248-4 · Cited by 1,655
Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., De Carvalho, N. S., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17398-4 · Cited by 1,643
Villa, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., Wheeler, C. M., Koutsky, L. A., Malm, C., Lehtinen, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70101-7 · Cited by 1,579
Papillomaviruses in the causation of human cancers - a brief historical account
zur Hausen, H. (2009) · Virology · doi:10.1016/j.virol.2008.11.046 · Cited by 1,532
Structure and transcription of human papillomavirus sequences in cervical carcinoma cells
Schwarz, E., Freese, U. K., Gissmann, L., Mayer, W., Roggenbuck, B., Stremlau, A., & Hausen, H. Z. (1985) · Nature · doi:10.1038/314111a0 · Cited by 1,483
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
Joura, E. A., Giuliano, A. R., Iversen, O.-E., Bouchard, C., Mao, C., Mehlsen, J., Moreira, E. D., Ngan, Y., Petersen, L. K., Lazcano-Ponce, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405044 · Cited by 1,433
Ten Great Public Health Achievements—United States, 1900-1999
(1999) · JAMA · doi:10.1001/jama.281.16.1481 · Cited by 1,298
Petrosky, E. Y., Bocchini, J. A., Hariri, S., Chesson, H. W., Curtis, C. R., Saraiya, M., Unger, E. R., & Markowitz, L. E. (2015) · PubMed Central · Cited by 1,264
Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R., & Schiller, J. T. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12180 · Cited by 1,110
Jemal, A., Simard, E. P., Dorell, C., Noone, A.-M., Markowitz, L. E., Kohler, B., Eheman, C., Saraiya, M., Bandi, P., Saslow, D., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs491 · Cited by 993
HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia
Palefsky, J. M., Giuliano, A. R., Goldstone, S., Moreira, E. D., Aranda, C., Jessen, H., Hillman, R., Ferris, D., Coutlee, F., Stoler, M. H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010971 · Cited by 948 · cited 1×
“Clinical trial data among MSM who have been vaccinated with 4vHPV demonstrate a reduced risk of anal cancer [76], an important outcome for this population that has higher rates of this cancer [77].”
BackgroundLe, M., Dunne, E. F., Saraiya, M., Chesson, H. W., Curtis, C. R., Gee, J. M., Bocchini, J. A., & Unger, E. R. (2014) · PubMed · Cited by 924
The Feminization of American Culture
Voloshin, B. R., & Douglas, A. (1977) · The New England Quarterly · doi:10.2307/364262 · Cited by 867
Reagan-Steiner, S., Yankey, D., Jeyarajah, J., Elam-Evans, L. D., Singleton, J. A., Curtis, C. R., MacNeil, J., Markowitz, L. E., & Stokley, S. (2015) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6429a3 · Cited by 834
Woodman, C. B., Collins, S., Winter, H., Bailey, A., Ellis, J., Prior, P., Yates, M., Rollason, T. P., & Young, L. S. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04956-4 · Cited by 822
Villa, L. L., Costa, R. L. R., Petta, C. A., Andrade, R. P., Paavonen, J., Iversen, O.-E., Olsson, S.-E., Høye, J., Steinwall, M., Riis-Johannessen, G., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603469 · Cited by 806
Meites, E., Kempe, A., & Markowitz, L. E. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6549a5 · Cited by 802 · cited 1×
“Most recently, in October 2016 the FDA approved and in December 2016 ACIP recommended a two-dose option for 9vHPV for males and females ages 9 through 14 years, Individuals must be vaccinated before age 15, and follow a 0 and 6–12 month vaccine delivery schedule [46,47].”
BackgroundHuman Papillomaviruses and Their Possible Role in Squamous Cell Carcinomas
zur Hausen, H. (1977) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-66800-5_1 · Cited by 710
The Estimated Lifetime Probability of Acquiring Human Papillomavirus in the United States
Chesson, H. W., Dunne, E. F., Hariri, S., & Markowitz, L. E. (2014) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000000193 · Cited by 706 · cited 1×
“It is estimated that nearly 85% of women and 91% of men with at least one sexual partner from the opposite sex will contract HPV infection during their lifetime [53].”
BackgroundDrolet, M., Bénard, É., Boily, M.-C., Ali, H., Baandrup, L., Bauer, H., Beddows, S., Brisson, J., Brotherton, J. M. L., Cummings, T., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)71073-4 · Cited by 642
Condylomata acuminata and human genital cancer.
Hausen, H. Z. (1976) · PubMed · Cited by 583
Chapter 6: Epidemiology and transmission dynamics of genital HPV infection
Burchell, A. N., Winer, R. L., de Sanjosé, S., & Franco, E. L. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.031 · Cited by 529
Markowitz, L. E., Hariri, S., Lin, C., Dunne, E. F., Steinau, M., McQuillan, G., & Unger, E. R. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit192 · Cited by 521
Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study
Giuliano, A. R., Lee, J.-H., Fulp, W., Villa, L. L., Lazcano, E., Papenfuss, M. R., Abrahamsen, M., Salmeron, J., Anic, G. M., Rollison, D. E., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62342-2 · Cited by 500
Villa, L. L., Ault, K. A., Giuliano, A. R., Costa, R. L. R., Petta, C. A., Andrade, R. P., Brown, D. R., Ferenczy, A., Harper, D. M., Koutsky, L. A., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.04.068 · Cited by 469
Predictors of HPV vaccine uptake among women aged 19–26: Importance of a physician's recommendation
Rosenthal, S. L., Weiss, T. W., Zimet, G. D., Ma, L., Good, M. B., & Vichnin, M. D. (2011) · Vaccine · doi:10.1016/j.vaccine.2009.12.063 · Cited by 458
Self-citationHuman papillomavirus type‐16‐related DNA in genital Bowen's disease and in bowenoid papulosis
Ikenberg, H., Gissmann, L., Gross, G., Grussendorf‐Conen, E., & Hausen, H. Z. (1983) · International Journal of Cancer · doi:10.1002/ijc.2910320507 · Cited by 439 · cited 1×
“In addition to identifying HPV as a cause for cervical cancer, other studies investigated HPV's connection to anogenital cancers, including penile and anal cancers [36,37].”
BackgroundRe‐thinking the “Feminization of Poverty” in Relation to Aggregate Gender Indices
Chant, S. (2006) · Journal of Human Development · doi:10.1080/14649880600768538 · Cited by 394
Prevalence of HPV After Introduction of the Vaccination Program in the United States
Markowitz, L. E., Liu, G., Hariri, S., Steinau, M., Dunne, E. F., & Unger, E. R. (2016) · Pediatrics · doi:10.1542/peds.2015-1968 · Cited by 383
Human Papillomavirus Vaccine Introduction – The First Five Years
Markowitz, L. E., Tsu, V., Deeks, S. L., Cubie, H., Wang, S. A., Vicari, A. S., & Brotherton, J. M. L. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.05.039 · Cited by 364
Quadrivalent Human Papillomavirus Vaccine
Gellin, B., Modlin, J. F., Barr, E., & Tamms, G. (2007) · Clinical Infectious Diseases · doi:10.1086/520654 · Cited by 330
Giuliano, A. R., Nyitray, A. G., Kreimer, A. R., Pierce, C. M., Goodman, M. T., Sudenga, S. L., Monsonégo, J., & Franceschi, S. (2014) · International Journal of Cancer · doi:10.1002/ijc.29082 · Cited by 308
The Feminization of American Culture
Durning, R. E., & Douglas, A. (1978) · The American Historical Review · doi:10.2307/1862479 · Cited by 286
Catarino, R. (2015) · World Journal of Clinical Oncology · doi:10.5306/wjco.v6.i6.281 · Cited by 284 · cited 1×
“The global burden from cervical cancer was far greater in developing nations than in developed nations that had implemented highly effective screening programs, which resulted in lower rates of cancer deaths [21].”
BackgroundThe role of HPV in head and neck cancer and review of the HPV vaccine
D'Souza, G., & Dempsey, A. (2011) · Preventive Medicine · doi:10.1016/j.ypmed.2011.08.001 · Cited by 267 · cited 1×
“Yet, there are no straightforward pre-clinical endpoints for oropharyngeal cancers, nor are there any approved screening techniques similar to cervical cancer [84], making it difficult to conduct rigorous shorter-term studies demonstrating that HPV vaccination prevents pre-oropharyngeal cancers.”
BackgroundMeites, E., Kempe, A., & Markowitz, L. E. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14206 · Cited by 240
Beliefs, behaviors and HPV vaccine: Correcting the myths and the misinformation
Zimet, G. D., Rosberger, Z., Fisher, W. A., Perez, S., & Stupiansky, N. W. (2013) · Preventive Medicine · doi:10.1016/j.ypmed.2013.05.013 · Cited by 227
Self-citationPetroll, A. E., & Mosack, K. E. (2011) · Sexually Transmitted Diseases · doi:10.1097/olq.0b013e3181ebd50f · Cited by 225 · cited 1×
“behavior, resulting in missed opportunities for HPV vaccination [78,79].”
BackgroundHPV Vaccine Hesitancy: Findings From a Statewide Survey of Health Care Providers
McRee, A.-L., Gilkey, M. B., & Dempsey, A. F. (2014) · Journal of Pediatric Health Care · doi:10.1016/j.pedhc.2014.05.003 · Cited by 217
Gilkey, M. B., Malo, T. L., Shah, P. D., Hall, M. E., & Brewer, N. T. (2015) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0326 · Cited by 211
The cost-effectiveness of male HPV vaccination in the United States
Chesson, H. W., Ekwueme, D. U., Saraiya, M., Dunne, E. F., & Markowitz, L. E. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.07.096 · Cited by 204
Kim, J. J. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70219-x · Cited by 182 · cited 1×
“The extension of the age recommendation to high-risk subgroups was the result of costeffectiveness data indicating that MSM are at higher risk of anal cancers and genital warts [41], and would receive additional benefit from vaccination at later age ranges compared to heterosexual males.”
BackgroundPower and Bodily Practice: Applying the Work of Foucault to an Anthropology of the Body
Pylypa, J. (1998) · UA Campus Repository (The University of Arizona) · Cited by 174
Ten Great Public Health Achievements—Worldwide, 2001-2010
Koppaka, R. (2011) · JAMA · doi:10.1001/jama.306.5.484 · Cited by 159
The male pill: a biography of a technology in the making
(2004) · Choice Reviews Online · doi:10.5860/choice.41-4074 · Cited by 159
Sex, drugs, and politics: the HPV vaccine for cervical cancer
Casper, M. J., & Carpenter, L. M. (2008) · Sociology of Health & Illness · doi:10.1111/j.1467-9566.2008.01100.x · Cited by 147
Reiter, P. L., McRee, A., Pepper, J. K., Gilkey, M. B., Galbraith, K. V., & Brewer, N. T. (2013) · American Journal of Public Health · doi:10.2105/ajph.2012.301189 · Cited by 147
Cancer in a Population-based Cohort of Men and Women in Registered Homosexual Partnerships
Frisch, M. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg067 · Cited by 146 · cited 1×
“Clinical trial data among MSM who have been vaccinated with 4vHPV demonstrate a reduced risk of anal cancer [76], an important outcome for this population that has higher rates of this cancer [77].”
BackgroundDo correlates of HPV vaccine initiation differ between adolescent boys and girls?
Gilkey, M. B., Moss, J. L., McRee, A., & Brewer, N. T. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.07.045 · Cited by 119
HPV Vaccination Mandates — Lawmaking amid Political and Scientific Controversy
Colgrove, J. K., Abiola, S. E., & Mello, M. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmsr1003547 · Cited by 115 · cited 1×
“An alternative strategy for HPV vaccination mandates is through health departments [51].”
BackgroundRearranged HPV 16 molecules in an anal and in a laryngeal carcinoma
Scheurlen, W. G., Stremlau, A., Gissmann, L., Höhn, D., Zenner, H., & Hausen, H. Z. (1986) · International Journal of Cancer · doi:10.1002/ijc.2910380509 · Cited by 105 · cited 1×
“In addition to identifying HPV as a cause for cervical cancer, other studies investigated HPV's connection to anogenital cancers, including penile and anal cancers [36,37].”
BackgroundBartlett, J. A., & Peterson, J. A. (2011) · The Journal of School Nursing · doi:10.1177/1059840511415861 · Cited by 100
Tempest in a teapot: A systematic review of HPV vaccination and risk compensation research
Kasting, M. L., Shapiro, G. K., Rosberger, Z., Kahn, J. A., & Zimet, G. D. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1141158 · Cited by 96
Self-citationHuman Papilloma Viruses and Cancer1
Hausen, H. Z., Gissmann, L., Steiner, W., Dippold, W. G., & Dreger, I. (2015) · Proceedings of the International Symposium on Comparative Leukemia Research · doi:10.1159/000399220 · Cited by 74
Comparing human papillomavirus vaccine knowledge and intentions among parents of boys and girls
Lindley, M. C., Jeyarajah, J., Yankey, D., Curtis, C. R., Markowitz, L. E., & Stokley, S. K. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1157673 · Cited by 72
Dodd, R. H., McCaffery, K. J., Marlow, L. A. V., Ostini, R., Zimet, G. D., & Waller, J. (2014) · Sexually Transmitted Infections · doi:10.1136/sextrans-2013-051402 · Cited by 68
Self-citationReimer, R. A., Schommer, J. A., Houlihan, A. E., & Gerrard, M. (2013) · Journal of Community Health · doi:10.1007/s10900-013-9773-y · Cited by 65 · cited 1×
“As a result of the delay in male HPV vaccine approval, studies have indicated that females have a greater awareness and knowledge of the HPV vaccine compared to males [85,86].”
BackgroundPolzer, J., & Knabe, S. (2012) · The Journal of Sex Research · doi:10.1080/00224499.2011.644598 · Cited by 42 · cited 1×
“Given that the goal of the marketing campaign was to increase vaccine uptake, it is likely that Merck attempted to avoid these discussions among the American public who often stigmatize, politicize, and misrepresent sexual health issues [68,69].”
BackgroundIncluding males in Canadian human papillomavirus vaccination programs: a policy analysis
Shapiro, G. K., Perez, S., & Rosberger, Z. (2016) · Canadian Medical Association Journal · doi:10.1503/cmaj.150451 · Cited by 37
Self-citationWingood, G. M. (2003) · Journal of Heredity · doi:10.1093/jurban/jtg084 · Cited by 36
Fisher, J. A., & Ronald, L. M. (2008) · Advances in medical sociology · doi:10.1016/s1057-6290(08)10003-1 · Cited by 26 · cited 1×
“Additionally, this initial marketing campaign failed to directly address the sexual transmission of HPV and the implications for the prevention of genital warts [67,68].”
BackgroundGottlieb, S. D. (2013) · Medical Anthropology Quarterly · doi:10.1111/maq.12046 · Cited by 24
Running, health and the disciplining of women's bodies: The influence of technology and nature
Little, J. (2016) · Health & Place · doi:10.1016/j.healthplace.2016.11.011 · Cited by 22
Merck'sOne LessCampaign: Using Risk Message Frames to Promote the Use of Gardasil® in HPV Prevention
Grantham, S., Ahern, L. A., & Connolly-Ahern, C. (2011) · Communication Research Reports · doi:10.1080/08824096.2011.616243 · Cited by 21 · cited 1×
“The preliminary 4vHPV marketing (“One Less” campaign [64]) understandably framed the vaccine from the cervical cancer prevention standpoint and voiced female empowerment as a reason for vaccination [65].”
BackgroundHuman papillomavirus (HPV) vaccination and the development of public policies
Lippman, A. (2008) · Journal of Epidemiology & Community Health · doi:10.1136/jech.2008.074740 · Cited by 17 · cited 2×
“Additionally, this initial marketing campaign failed to directly address the sexual transmission of HPV and the implications for the prevention of genital warts [67,68].”
BackgroundWestbrook, L., & Fourie, I. (2015) · Journal of Documentation · doi:10.1108/jd-09-2014-0124 · Cited by 15
What is it to Share Contraceptive Responsibility?
Davis, E. (2015) · Topoi · doi:10.1007/s11245-015-9342-3 · Cited by 11 · cited 1×
“Specifically, contraception is more costly for women (financially and physically), and women are the focus of procreative responsibility, thus bearing the burden of the contraception responsibility [7].”
BackgroundGendering Gardasil: Framing Gender and Sexuality in Media Representations of the HPV Vaccine
Pisciotta, M. (2000) · doi:10.15760/etd.807 · Cited by 11 · cited 2×
“An unfortunate and unintended consequence of this campaign was a skewed view that HPV impacted only females [66].”
Background
Cited by
Hirth, J. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1512453 · Cited by 256
Metadata
- Authors
- Daley, E. M., Vamos, C. A., Thompson, E. L., Zimet, G. D., Rosberger, Z., Merrell, L., & Kline, N. S.
- Venue
- Papillomavirus Research
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 3
- Pages
- 142-148
- ISSN
- 2405-8521 (ISSN-L)
- OpenAlex
- W2605470218
- Cited by
- 167
- References
- 74
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.